tbuckley/cabot-search huggingface dataset:
Interest of DCE-US with quantification to demonstrate the VDA effect on vascularization in patients with advanced solid tumors treated with AVE8062
Authors: M. Chebil, J. Soria, L. Chami, C. Massard, B. Benatsou, A. Roche, J. Armand, N. Lassau
Journal: Journal of Clinical Oncology (2009)

e14522 Background: To determine the optimal time for the assessment of the perfusion in patients receiving AVE8062 (Vascular Disrupting Agent) at different doses combined with a fixed dose of cisplatin and then to correlate these results with the tumor response. Methods: Patients (pts) with advanced solid tumors, treated with AVE8062 (from 11.5 to 30 mg/m 2 ) in combination with 75 mg/m 2 cisplatin given every 3 weeks, were prospectively followed by DCE-US. DCE-US was performed before treatment, at 3 time points (0, 6 and 24 hours (h)) on Day 1 of the first (C1) and second cycle (C2), then every 2 cycles thereafter. Contrast uptake was acquired using VRI perfusion software after SonoVue bolus injection. Time-Intensity Curves (TIC) were determined using linear raw- data from CHI-Q (Toshiba) software. Peak Intensity (PI) representing the blood volume was calculated from automatic modeling of TIC. CT-scans performed before treatment and every 2 cycles were reviewed and tumor response assessed (RECIST). Results: A total of 96 DCE-US were performed in 13 pts, 11 of whom had data for both cycle 1 and cycle 2. Among these 11 patients, 8 presented with a dramatic decrease of PI and 3 with an increase of PI. At cycle 1, mean change from baseline in PI was -36% at 6h and -47% at 24h after AVE8062 infusion. Greater decreases were observed at cycle 2, -70% at 6 h and 78% at 24 h. No pt had a clinical response, but by cycle 2, the 8 pts with a decrease in PI at 24h went on to have stable disease as best response; 3 pts with increased PI 24h after their second treatment all had disease progression as best response. Conclusions: The best timing to observe the effect of AVE8062 on the PI seems to be 24 hours after drug administration at cycle 2. These preliminary results suggest that 24 hr PI at cycle 2 could be useful for determining pts who are more likely to have disease progression as best response to AVE8062. If confirmed, the assessment of PI variation may predict the clinical response to AVE8062. Further studies are needed to assess the possible predictive value of DCE-US on duration of progression-free survival. No significant financial relationships to disclose.
Micro-complement fixation: a quantitative estimator of protein evolution.
Authors: R D Maxson, L R Maxson
Journal: Molecular Biology and Evolution (1986)

The quantitative immunological technique of micro-complement fixation (MC'F) has been routinely used during the past decade to assess evolutionary relationships among living vertebrate species. The large data base that has been generated, along with the excellent correlations between immunologically measured genetic distances and paleontologically derived estimates of divergence times, have formed the basis for the albumin molecular clock. Immunological distance (ID) involves a logarithmic transformation of experimentally measured antibody concentrations. The justification for this transformation has rested entirely on empirical correlations. Consequently, several other transformations have been proposed as giving better fits to particular data sets. We derive, from first principles, the relationship between ID and the amino acid sequence replacements (AAR) between compared albumins. ID is shown to be a linear estimator of AAR. This ID-AAR relationship is based on a proposed process of antibody assortment and exclusion. We present experimental data confirming that such an antibody assortment-exclusion process occurs in MC'F. This process can explain both the high sensitivity and the quantitative phylogenetic nature of the MC'F assay. The assortment-exclusion process also predicts a divergence limit beyond which MC'F data no longer provide robust phylogenetic data.
Development of a composite index for clinical trials in early diffuse cutaneous systemic sclerosis - the combined response index in systemic sclerosis
Authors: D. Khanna, V. Berrocal, E. Giannini, M. Mayes, P. Merkel, J. Siegel, J. Seibold, M. Baron, P. Clements, Y. Allanore, V. Steen, C. Denton, O. Distler, S. Johnson, M. Matucci-Cerinic, L. Czirjak, J. Pope, S. Proudman, W. Wong, A. Wells, D. Furst
Journal: Arthritis & Rheumatology (2014)
Epstein-Barr virus-associated B-cell lymphoproliferative disorders in immunodeficiency: meeting the challenge.
Authors: R S Shapiro
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.3.371 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2155305 Epstein-Barr virus-associated B-cell lymphoproliferative disorders in immunodeficiency: meeting the challenge. R S ShapiroxR S ShapiroSearch for articles by this author Show More University of Minnesota, Minneapolis. https://doi.org/10.1200/JCO.1990.8.3.371 First Page PDF © 1990 by American Society of Clinical Oncology
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to chemotherapy with S-1 as well as a prognostic factor for survival of patients after S-1 chemotherapy
Authors: K. Uchida, K. Hayashi, K. D. Danenberg, S. Schneider, H. Kuramochi, K. Takasaki, P. V. Danenberg
Journal: Journal of Clinical Oncology (2004)

3642 Background:Cyclooxygenase-2 (COX-2) has an important role in tumor development. Although a number of studies have found high expression of COX-2 to be an unfavorable prognostic factor, the influence of COX-2 expression levels on tumor response to chemotherapy has been relatively little studied. The purpose of this study was to discover if there is a relationship between COX-2 gene expression and chemosensitivity of tumors in clinical treatment of colorectal tumors with the fluoropyrimidine based therapy S-1. Patients & Methods:Forty pts with advanced (stage IV) CRC were treated with S-1 twice daily (BSA=1.5m2, 60mg/day ) for 28 days followed by a 2-week period rest . mRNA was isolated from paraffin-embedded pretreatment primary tumor specimens, and relative expression levels of each COX-2/b-actin were measured using a quantitative reverse transcription polymerase chain reaction (RT-PCR) (Taqman“) system. Results:The overall response rate of this group of patients to S-1 was 40.9%. COX-2 mRNA expression was detectable in 40 patients. COX-2 gene expression was significantly lower in the responding tumors compared to the non-responders respectively (P= 0.016, Mann-Whitney U test). Patients with COX-2 values above the median for all patients had a significantly shorter survival than those with COX-2 gene expressions below the median. Conclusions:Intratumoral COX-2 gene expression is a predictive factor for response to chemotherapy with S-1 as well as a prognostic factor for survival of patients after S-1 chemotherapy. These results suggest that combination therapy of S-1 and COX-2 inhibitors may provide more effective treatment for patients with CRC than S-1 alone, whereas measurement of COX-2 status may identify patients with a lower probability of response and unfavorable prognosis. No significant financial relationships to disclose.
Gene profiling validation for cancer classification using known primary carcinoma samples
Authors: R. Lenzi, A. Rashid, N. Ordonez, N. M. Raber, G. R. Varadhachary, A. Floore, L. Stork-Sloots, M. Warmoes, M. Erlander, J. L. Abbruzzese
Journal: Journal of Clinical Oncology (2007)

21130 Background: Cancer of Unknown Primary Site (CUP) accounts for 3–5% of all malignant neoplasms. With current diagnostic procedures, approximately 20% of CUP patients have a primary identified. Since formulation of prognosis and treatment selection depends largely on the primary type, diagnostic uncertainty unfavorably affects CUP management. Gene expression profiling has permitted the development of diagnostic classifiers. A clinically usable methodology needs to differentiate a sufficiently large number of primary types. This study focuses on the estimate of the accuracy of gene expression for classification of metastatic tumors in formalin fixed (FF) FNA and core/surgical biopsies. Methods: CupPrint® is a 1900 gene microarray optimized for FF samples which uses a database of 643 cancer profiles to provide a robust method for the discrimination of 51 tumor (sub) types. Metastasis samples of six known primary carcinoma types were studied (lung, pancreas, colorectal, breast, liver, ovary/primary peritoneal carcinoma). To examine the impact of the metastatic site on diagnostic accuracy different biopsy sites were studied, including lung, brain, lymph nodes, liver, peritoneum. Samples were deemed evaluable that contained an estimated &gt;33% tumor cells. mRNA samples from the metastatic lesions were provided in a blinded fashion to the microarray laboratory. Results: For 39 evaluable samples studied so far, the CupPrint® prediction was compared with the pathologic diagnosis. Of the 39, in 34 the primary site of origin was correctly predicted (87% accuracy). In two of the incorrectly predicted samples the site of biopsy (brain and liver respectively) was reported as the primary site. Correlations of molecular profiles to clinical parameters are being explored. Conclusions: CupPrint® appears to be sufficiently accurate to be of potential clinical utility in the diagnosis of CUP. No significant financial relationships to disclose.
Incidence and predictors of post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction undergoing biliary or dual sphincterotomy: results from the EPISOD prospective multicenter randomized sham-controlled study
Authors: Mohammad Yaghoobi, Qi Pauls, Valerie Durkalski, Joseph Romagnuolo, Evan Fogel, Paul Tarnasky, Giuseppe Aliperti, Martin Freeman, Richard Kozarek, Priya Jamidar, Charles Wilcox, Grace Elta, Robert Hawes, April Wood-Williams, Peter Cotton
Journal: Endoscopy (2015)

<b>Background and study aim:</b> Pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) is a significant and potentially life-threatening adverse event and is common in patients with suspected sphincter of Oddi dysfunction (SOD). Here we aimed to identify predictors of the risk in this population. <b>Patients and methods:</b> The Evaluating Predictors and Interventions in SOD (EPISOD) study prospectively enrolled 214 post-cholecystectomy patients with SOD type III in seven US centers. Patients were randomized, using a 2:1 allocation, to sphincterotomy or sham procedure, irrespective of the results of sphincter of Oddi manometry. Patients in the sphincterotomy arm who had elevated pancreatic sphincter pressure were randomized to biliary only or to dual (biliary and pancreatic) sphincterotomy. All but one patient received prophylactic pancreatic stents, but none received pharmacological prophylaxis. Post ERCP pancreatitis (PEP) was defined as acute pancreatitis within the subsequent 7 days. Blinded research coordinators at each site called patients at 1 week post-procedure. <b>Results:</b> PEP occurred in 26 patients, in 10.6 % (15/141) in the sphincterotomy arm and 15.1 % (11/73) in the sham arm; unadjusted relative risk 0.71 (95 % confidence interval [95 %CI] 0.34 – 1.46). PEP rate was not significantly different in patients who received sphincterotomy compared with those undergoing sham treatment. In addition, the proportion was not statistically different in those who received biliary sphincterotomy alone (12/94; 12.8 % [95 %CI 6.0 % – 19.5 %]) compared with dual sphincterotomy (3/47; 6.4 % [95 %CI 0.0 % – 13.4 %]). Multivariate analysis identified an interaction between duration of ERCP and sedation type (<i>P</i> < 0.02). <b>Conclusion:</b> The performance of biliary or dual sphincterotomy does not increase the risk of PEP in patients suspected of SOD. However, the high rate of PEP in patients with suspected SOD, despite pancreatic stenting in expert centers, is confirmed in this prospective study. The combined effect of duration of ERCP and sedation type on the development of PEP should be further explored. Clinicaltrials.gov registration: NCT00688662
Comparison of neoadjuvant paclitaxel and carboplatin with neoadjuvant letrozole in postmenopausal patients with receptor-positive locally advanced breast cancer (LABC)
Authors: D. Sinha, A. K. Bahadur, K. Singh, A. K. Rathi
Journal: Journal of Clinical Oncology (2009)

608 Background: For the treatment of LABC using a regimen with the highest likelihood of shrinking the tumor should improve the outcome. Paclitaxel was the first taxane to show activity in breast cancer. The advent of endocrine therapy in the neoadjuvant setting allows downstaging of tumors with less morbidity. The aromatase inhibitors are now the treatment of choice in neoadjuvant setting for elderly patients with estrogen receptor-positive breast cancer. Methods: This prospective, randomized, comparative study assessed the effect of three cycles of neoadjuvant chemotherapy vs. three months of neoadjuvant hormonal therapy in terms of loss of clinical and pathological primary tumor size. Inclusion criteria required postmenopausal patients with non-metastatic, ER and/or PR positive LABC with no co-morbidity. Forty eligible patients were randomly assigned into 2 groups of 20 patients each: Group A treated with 3 cycles of 3 weekly injections of paclitaxel (175 mg/m 2 ) and carboplatin (AUC 6) assessed after each cycle; group B received oral Letrozole 2.5mg once daily for 3 months assessed every 4 weeks. Surgery was done and primary specimen was pathologically examined. Results: Clinically mean loss in primary residual tumor compared to volume at presentation in group A vs. group B at 1st review was 45% vs. 35% (p: 0.536), 63% vs. 57% at second (p: 0.176), and 71% vs. 74% at third review (p: 0.062).Clinical complete response (WHO criteria) and stable disease each were seen in 14% in either group of patients (p: 0.632), partial response in 65% group A and in 72% group B (p: 0.117); no progressive disease was seen in either. All patients underwent surgery. The mean pathological primary cell kill in group A vs. group B was 81% vs.78 %(p:0.918). Resected nodes were pathologically positive for tumor in 47% group A and 60% group B patients (p: 0.269). Conclusions: Neoadjuvant hormonal therapy using oral Letrozole in receptor positive LABC in post menopausal women is as effective as three weekly paclitaxel and carboplatin in downstaging the tumor. No significant financial relationships to disclose.
Mind and mood in modern art, II: Depressive disorders, spirituality, and early deaths in the abstract expressionist artists of the New York School
Authors: J J Schildkraut, A J Hirshfeld, J M Murphy
Journal: American Journal of Psychiatry (1994)

This article documents the high prevalence of mood disorders in a group of 15 of the mid-twentieth-century Abstract Expressionist artists of the New York School. These artists, using the technique of psychic automatism (based on free association) in order to reveal unconscious material, created a psychologically and spiritually significant art that addressed the mythic themes of creation, birth, life, and death. Over 50% of the 15 artists in this group had some form of psychopathology, predominantly mood disorders and preoccupation with death, often compounded by alcohol abuse. At least 40% sought treatment and 20% were hospitalized for psychiatric problems. Two committed suicide; two died in single-vehicle accidents while driving; and two others had fathers who killed themselves. Many of these artists died early deaths, and close to 50% of the group (seven of 15) were dead before the age of 60. The material presented in this article suggests the following formulation and hypothesis. Depression inevitably leads to a turning inward and to the painful reexamination of the purpose of living and the possibility of dying. Thus, by bringing the artist into direct and lonely confrontation with the ultimate existential question, whether to live or to die, depression may have put these artists in touch with the inexplicable mystery that lies at the heart of the "tragic and timeless" art that the Abstract Expressionists aspired to produce.
GW26-e4531 The Clinical Observation of Cardiac Resynchronization Therapy in Patients with Chronic Heart Failure
Authors: Dongming Xie, Jiayuan Lin, Yihong Yang, Zhanglin Yan, Xiangzhong Liao, Xufeng Zhou, Jiumei Cai, Gulao Zhang, Shike Luo, Zuofeng Cao, Yuping Lin, Wenting Zhong, Xinguang Chen, Haiying Chang, He Huang, Mei Zhong, Jinhai Zhu, Bei Wang, Ping Lai, Kun Xiao
Journal: Journal of the American College of Cardiology (2015)
Is there a dynamic illusion effect in the motor system?
Authors: Volker H. Franz
Journal: Behavioral and Brain Sciences (2004)

Glover's planning–control model is based on his finding that visual illusions exert a larger effect in early phases than in late phases of a movement. But evidence for this dynamic illusion effect is weak, because: (a) it appears difficult to replicate; (b) Glover overestimates the accuracy of his results; and (c) he seems to underestimate the illusion effect at late phases.
ENTEROVIRAL RIBONUCLEIC ACID
Authors: John J. Holland, Leroy C. McLaren, Bill H. Hoyer, Jerome T. Syverton
Journal: The Journal of Experimental Medicine (1960)

Chromatographic behavior of whole type 1 poliovirus and phenol-extracted viral RNA on diethylaminoethyl cellulose columns, as revealed by assay of plaque-forming capacity, indicated that infectious RNA had surface properties markedly different from those of the intact virus. Infectious RNA of type 1 poliovirus and Coxsackie B1 virus was relatively resistant to heat inactivation as compared to intact virus. Kinetics of inactivation at elevated temperatures were multi-hit in character. The structure of infectious enterovirus RNA was investigated by treatment with chemical inactivating agents. Urea and guanidine as hydrogen bond-disrupting agents, and mercaptoethanol and thioglycolate as disulfide bond-disrupting agents, and combinations of these did not destroy RNA infectivity whereas hydrogen bond-disrupting treatment inactivated intact virus rapidly. RNA infectivity was not reduced by chloroform extraction alone, or by octanol extraction alone, but was reduced by chloroform-octanol extraction which failed to depolymerize RNA to an extent detectable by ultracentrifugal analysis. Infectivity of type 1 poliovirus and Coxsackie B1 virus RNA was destroyed in accordance with first order kinetics by very dilute solutions of pancreatic ribonuclease, and by purified snake venom phosphodiesterase, but not at all by bacterial alkaline phosphatase. Inactivation by venom diesterase was not accelerated by prior treatment of RNA with bacterial alkaline phosphatase. These results indicated that infectivity of enteroviral RNA resided in a single stranded structure, that a single break of a phosphodiester bond anywhere along the structure was sufficient to destroy infectivity, and that infectivity did not require a terminal phosphate group. Hydroxylamine, but not other carbonyl reagents, rapidly destroyed infectivity of intact type 1 poliovirus viral RNA without depolymerization of RNA-detectable by behavior in the analytical ultracentrifuge. With S35-methionine-labeled poliovirus a very small fraction of radioactivity remained in RNA preparations following phenol extraction. No evidence could be obtained to indicate that infectious enteroviral RNA was composed of subunits. RNA extracted with phenol during the course of infection of HeLa cells with type 1 poliovirus resembled RNA obtained from purified whole virus with respect to heat inactivation, hydroxylamine inactivation, chromatographic separation, susceptibility to protein denaturing agents, and ability to infect productively both naturally susceptible HeLa cells and naturally insusceptible L strain mouse cells. Intracellular production of infectious RNA paralleled intracellular maturation of whole virus and preceded it by a very short interval.
LI-cadherin expression in distant metastases of colorectal carcinoma: A potential differentiation marker.
Authors: D. B. Vangala, H. Lage, A. Thelen, S. Jonas, R. Gessner
Journal: Journal of Clinical Oncology (2010)

e14087 Background: LI-cadherin is a member of the group of 7D-cadherins. In humans, LI-cadherin is physiologically expressed in the basolateral cell membrane of the epithelia of the small and large intestine. However, expression has also been reported for colonic, gastric, pancreatic and hepatic adenocarcinomas as well as for intestinal metaplasia of the stomach. In this study we analyzed the expression of LI-cadherin in hepatic and pulmonary metastases of colorectal carcinomas and compared the expression to primary malignancies of these organs. Methods: We analyzed the expression of LI-cadherin in 77 primary malignant liver neoplasias (21 hepatocellular carcinomas, 56 cholangiocarcinomas), 28 colorectal liver metastases, 53 primary malignant lung carcinomas and 18 colorectal lung metastases. A polyclonal antibody raised against the cytoplasmatic domain of LI- cadherin was used to immunhistochemically stain paraffin embedded thin sections as well as tissue microarrays. Results: All colorectal liver metastases and 83 % of colorectal lung metastases showed strong, membrane specific staining for LI-cadherin. In contrast, none of the hepatocellular carcinomas and only 4 % of lung cancers were positive for LI-cadherin. In cholangiocarcinomas we observed positive staining in 27% of cases. Conclusions: LI-cadherin is strongly expressed at an early stage of malignant transformation and remains upregulated in distant metastases of colorectal carcinomas. Compared to that, E-cadherin is often downregulated in malignant tumors and in metastases. LI-cadherin expression could solely be observed in adenocarcinomas of entodermal origin and it may specifically serve as a histopathological differentiation marker for distant colorectal metastases. No significant financial relationships to disclose.
Intelligence, schizophrenia, and the corporate industry
Authors: Marcus Müllner
Journal: BMJ (2001)

According to a paper in this week's BMJ (p 819), better childhood mental ability predicts a longer life. Hundreds of promising sites on the web will allow you to measure your intelligence, creativity, sexuality, or emotional intelligence www.selfgrowth.com/test.html is just one of the many collections of links. I tried several of these tests: some are fun, some are …